Technical Analysis for SGEN - Seattle Genetics, Inc.

Grade Last Price % Change Price Change
grade A 74.64 0.58% 0.43
SGEN closed up 0.58 percent on Friday, August 17, 2018, on 56 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical SGEN trend table...

Date Alert Name Type % Chg
Aug 17 New 52 Week Closing High Bullish 0.00%
Aug 17 New 52 Week High Strength 0.00%
Aug 17 Overbought Stochastic Strength 0.00%
Aug 16 Doji - Bearish? Reversal 0.58%
Aug 16 New 52 Week High Strength 0.58%
Aug 16 Outside Day Range Expansion 0.58%
Aug 16 Overbought Stochastic Strength 0.58%
Aug 15 Narrow Range Bar Range Contraction 1.00%
Aug 15 NR7 Range Contraction 1.00%
Aug 15 Upper Bollinger Band Walk Strength 1.00%

Older signals for SGEN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Is SGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 74.76
52 Week Low 46.46
Average Volume 841,178
200-Day Moving Average 58.6648
50-Day Moving Average 69.3456
20-Day Moving Average 71.992
10-Day Moving Average 73.269
Average True Range 1.8801
ADX 34.08
+DI 23.9185
-DI 9.4243
Chandelier Exit (Long, 3 ATRs ) 69.1197
Chandelier Exit (Short, 3 ATRs ) 72.2003
Upper Bollinger Band 75.3934
Lower Bollinger Band 68.5906
Percent B (%b) 0.89
BandWidth 9.449383
MACD Line 1.6096
MACD Signal Line 1.5049
MACD Histogram 0.1047
Fundamentals Value
Market Cap 10.67 Billion
Num Shares 143 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -52.20
Price-to-Sales 20.40
Price-to-Book 15.26
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 76.35
Resistance 3 (R3) 76.20 75.48 76.07
Resistance 2 (R2) 75.48 75.04 75.56 75.97
Resistance 1 (R1) 75.06 74.78 75.27 75.21 75.87
Pivot Point 74.34 74.34 74.45 74.42 74.34
Support 1 (S1) 73.92 73.90 74.13 74.07 73.41
Support 2 (S2) 73.20 73.64 73.28 73.31
Support 3 (S3) 72.78 73.20 73.22
Support 4 (S4) 72.93